MSQ

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, FDA, MSQ, BioLineRx, PD-1, Drug development, Agility, Partnership, Pancreatic cancer, Patient, Sales, Pharmaceutical industry

Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.

Key Points: 
  • Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.
  • "Given GloriaBio's expertise and track record in the development and commercialization of cancer immunotherapies in China, we believe GloriaBio is well suited to further develop motixafortide in Asia.
  • The MSQ team showed remarkable agility and a deep understanding of mutual benefits to both parties right from our initial discussions.
  • As part of this momentous partnership, we eagerly anticipate the positive developments ahead, promising an even brighter future for global patients."

BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, FDA, MSQ, BioLineRx, PD-1, Drug development, Agility, Partnership, Pancreatic cancer, Patient, Sales, Pharmaceutical industry

Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.

Key Points: 
  • Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.
  • "Given GloriaBio's expertise and track record in the development and commercialization of cancer immunotherapies in China, we believe GloriaBio is well suited to further develop motixafortide in Asia.
  • The MSQ team showed remarkable agility and a deep understanding of mutual benefits to both parties right from our initial discussions.
  • As part of this momentous partnership, we eagerly anticipate the positive developments ahead, promising an even brighter future for global patients."

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

Retrieved on: 
Monday, August 7, 2023
Second Affiliated Hospital of Xinjiang Medical University, Visual analogue scale, Migraine, Depression, Prevalence, HHS, PSQI, MSQ, Clinical trial, World Health Organization, DSM-IV codes, Department of Neurology, Xuanwu hospital, Zhengzhou University, VAS, HAMA, Trial of the century, MDE, Pain, MDD, Patient, Grammatical mood, Pittsburgh Sleep Quality Index, Research, The Rheumatoid Arthritis Quality of Life Questionnaire, WHO, International Journal of Research in Marketing, Pharmaceutical industry, Brain

As part of the clinical study, 40 migraine patients (without migraine aura) were treated at the Vertigo Center.

Key Points: 
  • As part of the clinical study, 40 migraine patients (without migraine aura) were treated at the Vertigo Center.
  • The migraine study follows the Company’s recent clinical study in depression, which demonstrated statistically significant improvements among patients.
  • Mark White, CEO of Nexalin Technology, stated, "Research and Markets estimates the migraine and depression markets at roughly $3.9 billion and $11.2 billion, respectively.
  • We look forward to conducting additional clinical trials in new indications – many of which will be fully funded by Wider, our new JV partner.”

LBank Exchange Will List MSQUARE (MSQ) on July 21, 2023

Retrieved on: 
Thursday, July 20, 2023
Advertising, Small business, MSQ, Data collection, Government, Student, Icarus, Growth, We Are Messengers, Cryptocurrency, Metaverse

Road Town, British Virgin Islands--(Newsfile Corp. - July 20, 2023) -   LBank Exchange, a global digital asset trading platform, will list MSQUARE (MSQ) on July 21, 2023.

Key Points: 
  • Road Town, British Virgin Islands--(Newsfile Corp. - July 20, 2023) -   LBank Exchange, a global digital asset trading platform, will list MSQUARE (MSQ) on July 21, 2023.
  • For all users of LBank Exchange, the MSQ/USDT trading pair will be officially available for trading at 6:00 UTC on July 21, 2023.
  • Its native token, MSQ, will be listed on LBank Exchange at 6:00 UTC on July 21, 2023, with the goal of expanding its global footprint and supporting the realization of its forward-thinking objectives.
  • LBank Exchange is thrilled to announce the upcoming listing of MSQUARE (MSQ), a foundation that issues and operates MSQ tokens and is a startup company that directly plans, develops, and operates global real economy platforms.

One Equity Partners to Acquire MSQ Partners, a Marketing & Digital Transformation Group

Retrieved on: 
Monday, June 12, 2023
Banking, Software, Networks, Professional Services, Data Management, Technology, Other Communications, Other Professional Services, Marketing, Communications, Finance, Other Technology, Consulting, Advertising, Partnership, Food, Senior, One Equity Partners, VASS, Engineering, MSQ, OEP, Acquisition, Investment, Growth, Financial services

One Equity Partners (“OEP”), a middle market private equity firm, today announced it has acquired next generation creative and technology agency group MSQ Partners (“MSQ” or “the Group”).

Key Points: 
  • One Equity Partners (“OEP”), a middle market private equity firm, today announced it has acquired next generation creative and technology agency group MSQ Partners (“MSQ” or “the Group”).
  • The acquisition will serve as a platform for further consolidation within the tech-enabled marketing solutions and digital transformation sector.
  • “We are pleased to partner with MSQ to support the Group in its goal of becoming an international digital transformation champion and a leading technology-based creative services and marketing solutions provider,” said Dr. Joerg Zirener , Senior Managing Director, One Equity Partners.
  • In Europe, OEP’s track record includes investments and transformational combinations like Crayon, Engineering Ingegneria, Enthus, Kirey Group, Lutech, and VASS.

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

Retrieved on: 
Tuesday, May 30, 2023
Prevalence, CCCC, MSQ, Lung cancer, Mutation, NSCLC, Han Kun Law Offices, Development, Investigational New Drug, Patient, EGFR, Regulation, FDA, Therapy, IND, T790M, Disease, Pharmaceutical industry, Betta, Greater China

WATERTOWN, Mass. and HANGZHOU, China, May 30, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, and Betta Pharmaceuticals Co. Ltd (Betta) (SZ300558), a leading pharmaceutical company focusing on the development of innovative oncology therapies in China, today announced an exclusive licensing agreement for the development and commercialization of CFT8919 in Greater China (including Hong Kong SAR, Macau SAR and Taiwan). CFT8919 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer (NSCLC) patients.

Key Points: 
  • CFT8919 is an orally bioavailable BiDAC™ degrader designed to be potent and selective against EGFR L858R for non-small cell lung cancer (NSCLC) patients.
  • “We are excited to partner with Betta to develop CFT8919, an orally bioavailable allosteric EGFR L858R degrader, with the potential to treat NSCLC patients with EGFR L858R mutations in Greater China and beyond,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics.
  • In China, approximately 693,000 patients were diagnosed with NSCLC in 2020 and approximately 40% of these cases are driven by the EGFR mutation.
  • The L858R mutation is the second most common EGFR mutation, found in approximately 40% of NSCLC patients with EGFR mutations in China.

BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures

Retrieved on: 
Wednesday, June 29, 2022
BioLineRx, Patient, Thought, CEO, CXCR4, Disease, Cancer, MSQ, Anau, Partnership, PDAC, NASDAQ, Professional, Multimedia, Therapy, Pharmaceutical industry

Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet Therapeutics, Inc. , an immuno-oncology focused biopharmaceutical company based in Shanghai, China, for the development of Motixafortide in pancreatic ductal adenocarcinoma ("PDAC").

Key Points: 
  • Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet Therapeutics, Inc. , an immuno-oncology focused biopharmaceutical company based in Shanghai, China, for the development of Motixafortide in pancreatic ductal adenocarcinoma ("PDAC").
  • Under the terms of the agreement, GenFleet will design and execute a randomized Phase 2b clinical trial that will enroll approximately 200 first-line metastatic PDAC patients in China.
  • We are excited to see the alliance between BioLineRx and Genfleet to pursue the treatment of PDAC, which has proven to be incredibly challenging.
  • I am impressed by Phil's commitment to developing Motixafortide in PDAC which is also shared by GenFleet's Dr. Lu.

BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures

Retrieved on: 
Wednesday, June 29, 2022
BioLineRx, Patient, CEO, CXCR4, Disease, Cancer, MSQ, Anau, Partnership, PDAC, NASDAQ, Professional, Thought, Therapy, Pharmaceutical industry

Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet Therapeutics, Inc. , an immuno-oncology focused biopharmaceutical company based in Shanghai, China, for the development of Motixafortide in pancreatic ductal adenocarcinoma ("PDAC").

Key Points: 
  • Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet Therapeutics, Inc. , an immuno-oncology focused biopharmaceutical company based in Shanghai, China, for the development of Motixafortide in pancreatic ductal adenocarcinoma ("PDAC").
  • Under the terms of the agreement, GenFleet will design and execute a randomized Phase 2b clinical trial that will enroll approximately 200 first-line metastatic PDAC patients in China.
  • We are excited to see the alliance between BioLineRx and Genfleet to pursue the treatment of PDAC, which has proven to be incredibly challenging.
  • Ventures is aNew York-basedcross-border advisoryfirm that bridges thehealthcareindustries globally by offering our deep knowledge, strong network, and local insights into theChinamarket.

Lundbeck to Present Data on VYEPTI® (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention

Retrieved on: 
Thursday, June 9, 2022
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diamond, Woman, Eptinezumab, Neurological disorder, Caregiver, Headache, AHS, Research, Marketing, Lists of diseases, Nausea, Amitriptyline, Disease, Headache (journal), MHD, Steiner, Global Burden of Disease Study, Migraine, Failure, WPAI, CGRP, Disability, Patient, YLD, VAS, Calcitonin gene-related peptide, Topiramate, MSQ, Poster, LUN, Vomiting, Birth control, Pharmaceutical industry, Medical imaging, Aroma compound, Lundbeck, Virtual Private LAN Service

Lundbeck today announced data on VYEPTI (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS) taking place from June 9-12, 2022.

Key Points: 
  • Lundbeck today announced data on VYEPTI (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS) taking place from June 9-12, 2022.
  • A total of nine poster presentations will be shared to highlight clinical data and real-world analyses of eptinezumab as a preventive migraine treatment in adults.
  • These data continue to show the clinical benefit of VYEPTI as a preventive treatment option for people with migraine, said Marija Geertsen, M.D., Vice President, U.S. Medical Affairs, Lundbeck.
  • The safety of VYEPTI was evaluated in 2,076 patients with migraine who received at least one dose of VYEPTI.